DESCRIPTION:

FiteBac® K18/MMA

10% K18 formulated in liquid MMA

INDICATIONS FOR USE

Liquid MMA component for 2-part acrylate system

TARGET AUDIENCE:

Dental Laboratories

DEVELOPMENT STATUS:

Cleared for use in certain dental acrylics

PLANNED COMMERCIAL INTRODUCTION:

Q1/2019

BENEFITS:

Manufacture of dentures and retainers with long term antimicrobial resistance to biofilm formation.

DESCRIPTION:

FiteBac® Cavity Cleanser

2% K21 QAS aqueous ethanolic solution

INDICATIONS FOR USE

Intended for cleansing and moistening/re-wetting of cavity preparations

TARGET AUDIENCE:

Prescritpion use for Dental Professionals

DEVELOPMENT STATUS:

Under FDA Review

Q1/2019

PLANNED COMMERCIAL INTRODUCTION:

Q3/2019

BENEFITS:

Remove debris in carious lesion preparations and can penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface

DESCRIPTION:

FiteBac® CC Ortho-Seal

5% K18 in a dental sealant

INDICATIONS FOR USE

Sealant applied to enamel prior to placement of orthodontic bracket adhesive

TARGET AUDIENCE:

Prescription use for Dental Professionals

DEVELOPMENT STATUS:

510(k) Submission

Q2/2019

PLANNED COMMERCIAL INTRODUCTION:

Q4/2019

BENEFITS:

Resistance to biofilm formation around and under orthodontic brackets. Reduce risk of surface damage to surface enamel of teeth. Improved cosmetic outcomes.

DESCRIPTION:

FiteBac® FT Bond

5% K18 in a permanent acrylic based dental adhesive

INDICATIONS FOR USE

Permanent placement of dental appliances and restorations

TARGET AUDIENCE:

Prescription use for Dental Professionals

DEVELOPMENT STATUS:

510(k) submission

Q2/2019

PLANNED COMMERCIAL INTRODUCTION:

Q4/2019

BENEFITS:

Resistance to biofilm formation, loss of adhesion and decay under permanent dental restorations.